Following the Dollars: Why 340B Reform Is a Data-Driven Necessity

Hero_4

The 340B Drug Pricing Program is a lifeline for millions of patients and the providers that serve them—but rapid growth, increasing complexity, and limited data visibility are putting the program at risk.

As the program expands and overlaps with Medicaid, commercial contracts, and upcoming regulations like the Inflation Reduction Act’s Max Fair Price, compliance challenges and inefficiencies are growing.

This whitepaper explores the critical challenges facing manufacturers and covered entities, and why claims-level data is the key to protecting program integrity and improving outcomes.

Inside, you’ll learn:

  • The hidden compliance and operational risks in today’s 340B program and how they impact both providers and manufacturers
  • Why program overlap creates inefficiencies, waste, and the potential for duplicate discounts
  • How the current replenishment model limits visibility and makes detecting non-compliance difficult
  • Why a rebate model offers a data-driven path to transparency, streamlined operations, and risk reduction
  • Practical steps manufacturers can take now to collect and centralize claims data, even before regulatory changes take effect
  • How a centralized approach can build trust between manufacturers and covered entities while safeguarding patient access to care

Download the whitepaper to uncover actionable insights and a data-driven path to 340B reform that strengthens compliance, improves efficiency, and ensures that the patients who rely on 340B continue to get the care they need.

Fill out the form below to download the whitepaper now.

By submitting this form, I agree that Kalderos may contact me at the email address or phone number above to tell me about its services.